Expertise in
29
conditions

Dr. Loretta J. Nastoupil

Hematology Oncology | Hematology | Oncology
Catholic Health Initiatives Colorado
1 Mercado St, Suite 130, 
Durango, CO 
Offers Telehealth
Expertise in
29
conditions
Catholic Health Initiatives Colorado
1 Mercado St, Suite 130, 
Durango, CO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Loretta Nastoupil is a Hematologist Oncology specialist and a Hematologist in Durango, Colorado. Dr. Nastoupil is highly rated in 29 conditions, according to our data. Her top areas of expertise are Follicular Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Aspiration, and Tissue Biopsy.

Her clinical research consists of co-authoring 274 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in CO
Hospital Affiliations
Pagosa Springs Medical Center
San Juan Hospital
San Juan Regional Medical Center Inc
Southwest Memorial Hospital
Mercy Regional Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

CATHOLIC HEALTH INITIATIVES COLORADO
1 Mercado St, Suite 130, Durango, CO 81301

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase II Study of Obinutuzumab and Lenalidomide in Previously Untreated Subjects With Follicular Lymphoma
A Phase II Study of Obinutuzumab and Lenalidomide in Previously Untreated Subjects With Follicular Lymphoma
Enrollment Status: Completed
Publish Date: June 08, 2025
Intervention Type: Biological, Drug
Study Drugs: Lenalidomide, Obinutuzumab
Study Phase: Phase 2
A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Efficacy and Safety of Tisagenlecleucel (CTL019) in Adult Patients With Refractory or Relapsed Follicular Lymphoma
A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Efficacy and Safety of Tisagenlecleucel (CTL019) in Adult Patients With Refractory or Relapsed Follicular Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: May 16, 2025
Intervention Type: Biological
Study Drug: Tisagenlecleucel
Study Phase: Phase 2
A Phase 2, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
A Phase 2, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: May 01, 2025
Intervention Type: Drug, Biological
Study Drugs: TAK-007, Chemotherapy Agents
Study Phase: Phase 2
Phase II Study of Rituximab Plus Pembrolizumab (MK-3475) in Subjects With Relapsed Follicular Lymphoma
Phase II Study of Rituximab Plus Pembrolizumab (MK-3475) in Subjects With Relapsed Follicular Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: May 01, 2025
Intervention Type: Biological, Other, Drug
Study Drugs: Lenalidomide, Pembrolizumab, Rituximab
Study Phase: Phase 2
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: April 11, 2025
Intervention Type: Drug, Biological, Procedure
Study Drugs: Bendamustine Hydrochloride, Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Obinutuzumab, Prednisone, Umbralisib, Vincristine Sulfate
Study Phase: Phase 2
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
Enrollment Status: Completed
Publish Date: December 24, 2024
Intervention Type: Biological, Drug
Study Drugs: Axicabtagene Ciloleucel, Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders, Cyclophosphamide, Fludarabine
Study Phase: Phase 3
An Open Label, Phase 2 Study of Ibrutinib in Combination With Rituximab and Lenalidomide in Previously Untreated Subjects With Follicular Lymphoma and Marginal Zone Lymphoma
An Open Label, Phase 2 Study of Ibrutinib in Combination With Rituximab and Lenalidomide in Previously Untreated Subjects With Follicular Lymphoma and Marginal Zone Lymphoma
Enrollment Status: Completed
Publish Date: September 24, 2024
Intervention Type: Biological, Drug, Other
Study Drugs: Ibrutinib, Lenalidomide, Rituximab
Study Phase: Phase 2
ILyAD (Indolent Lymphoma And Vitamin D) A Phase III Double Blind, Randomized Trial to Evaluate the Effect of Vitamin D on Progression-free Survival in Patients With Low Tumor-burden Indolent Non-Hodgkin Lymphoma Treated With Rituximab
ILyAD (Indolent Lymphoma And Vitamin D) A Phase III Double Blind, Randomized Trial to Evaluate the Effect of Vitamin D on Progression-free Survival in Patients With Low Tumor-burden Indolent Non-Hodgkin Lymphoma Treated With Rituximab
Enrollment Status: Completed
Publish Date: September 04, 2024
Intervention Type: Other, Dietary supplement, Biological
Study Drugs: Cholecalciferol, Rituximab
Study Phase: Phase 3
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A (Apilimod Dimesylate Capsules) Administered Orally in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A (Apilimod Dimesylate Capsules) Administered Orally in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Enrollment Status: Completed
Publish Date: August 22, 2024
Intervention Type: Drug
Study Drugs: Apilimod, Rituximab, Atezolizumab
Study Phase: Phase 1
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study
Enrollment Status: Withdrawn
Publish Date: June 22, 2023
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Intravenous Doses of IGN002 Administered Weekly to Subjects With Refractory Non-Hodgkin Lymphoma (NHL)
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Intravenous Doses of IGN002 Administered Weekly to Subjects With Refractory Non-Hodgkin Lymphoma (NHL)
Enrollment Status: Terminated
Publish Date: March 11, 2022
Intervention Type: Biological
Study Drug: IGN002 Monoclonal Antibody Fusion Protein
Study Phase: Phase 1
An Open Label Ascending Dose Study Evaluating the Safety/Tolerability, Pharmacokinetic and Pharmacodynamic Effects of KA2237 In Patients With B Cell Lymphoma
An Open Label Ascending Dose Study Evaluating the Safety/Tolerability, Pharmacokinetic and Pharmacodynamic Effects of KA2237 In Patients With B Cell Lymphoma
Enrollment Status: Completed
Publish Date: February 06, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 11 Less Clinical Trials

274 Total Publications

Cytokine Storms in COVID-19, Hemophagocytic Lymphohistiocytosis, and CAR-T Therapy.
Cytokine Storms in COVID-19, Hemophagocytic Lymphohistiocytosis, and CAR-T Therapy.
Journal: JAMA network open
Published: April 07, 2025
Similar Doctors
Expertise in
61
conditions
Dr. Cynthia K. Cathcart
Oncology | Hematology
Expertise in
61
conditions
Dr. Cynthia K. Cathcart
Oncology | Hematology

Catholic Health Initiatives Colorado

1 Mercado St, 
Durango, CO 
 (0.1 mi)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Cynthia Cathcart is an Oncologist and a Hematologist in Durango, Colorado. Dr. Cathcart is highly rated in 61 conditions, according to our data. Her top areas of expertise are Paget Disease of the Breast, Chronic Lymphocytic Leukemia (CLL), Richter Syndrome, Familial Colorectal Cancer, and Bone Marrow Aspiration.

Expertise in
52
conditions
Dr. Jeffrey D. Neidhart
Hematology Oncology | Hematology | Oncology
Expertise in
52
conditions
Dr. Jeffrey D. Neidhart
Hematology Oncology | Hematology | Oncology

San Juan Oncology Associates P.C.

2325 E 30th St, 
Farmington, NM 
 (38.4 mi)
505-564-6850
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jeffrey Neidhart is a Hematologist Oncology specialist and a Hematologist in Farmington, New Mexico. Dr. Neidhart is highly rated in 52 conditions, according to our data. His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Aplastic Anemia, Gastrostomy, and Endoscopy. Dr. Neidhart is currently accepting new patients.

Expertise in
36
conditions
Dr. Sardar Z. Imam
Hematology Oncology | Hematology | Oncology
Expertise in
36
conditions
Dr. Sardar Z. Imam
Hematology Oncology | Hematology | Oncology

San Juan Oncology Associates P.C.

2325 E 30th St, 
Farmington, NM 
 (38.4 mi)
505-564-6850
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Sardar Imam is a Hematologist Oncology specialist and a Hematologist in Farmington, New Mexico. Dr. Imam is highly rated in 36 conditions, according to our data. His top areas of expertise are Lung Cancer, Paget Disease of the Breast, Adult Soft Tissue Sarcoma, Pleuropulmonary Blastoma, and Bone Marrow Aspiration. Dr. Imam is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nastoupil's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 7 Distinguished Conditions
View All 15 Advanced Conditions
View All 26 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile